CAR T-Cell Therapy clinical trials at UCSF
3 in progress, 2 open to eligible people
CAR T-cell therapy involves modifying cells to fight cancer. UCSF is examining the long-term effects of this therapy on patients. They are also researching if new drug treatments can help those with lymphoma after CAR T-cell therapy.
CAR-T Long Term Follow Up (LTFU) Study
open to eligible people ages 0-100
Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all…
San Francisco, California and other locations
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
open to eligible people ages 18 years and up
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel,…
San Francisco, California and other locations
MM CAR-T to Upgrade Response BMTCTN1902
Sorry, in progress, not accepting new patients
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among…
San Francisco, California and other locations
Our lead scientists for CAR T-Cell Therapy research studies include Madhav R. Seshadri.
Last updated: